TriangleNCT01891344 · OUTCOME
Overall Survival (Part 2 of Study)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- All patients in Part 2 were followed for survival, subsequent therapy, and secondary malignancy every 12 weeks until death, loss to follow-up, withdrawal of consent from study or study closure, whichever happened first, up to 7 years.
What was measured
Overall survival (OS) is defined as the number of days from the date of first dose of study drug to the date of death (due to any cause). Patients without a known date of death will be censored on the date the patient was last known to be alive.
Analysis population: Safety population by HRD subgroups: Consist of all Part 2 patients who received at least one dose of rucaparib.
Groups in this outcome
Part 2: tBRCA
Patients with a deleterious BRCA mutation detected in their tumor.
Part 2: Non-tBRCA LOH+
Patients without a BRCA mutation in their tumor, but have high LOH.
Part 2: Non-tBRCA LOH-
Patients without a BRCA mutation in their tumor, but have low LOH.
Part 2: Non-tBRCA LOH Unknown
Patients without a BRCA mutation in their tumor, and have unknown LOH due to missing results and/or failed test result(s).
| Group | Source count |
|---|---|
| Part 2: tBRCA | 84 |
| Part 2: Non-tBRCA LOH+ | 73 |
| Part 2: Non-tBRCA LOH- | 107 |
| Part 2: Non-tBRCA LOH Unknown | 23 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 2: tBRCA | 22.7 | Not reported | 16.7 | 28.6 | Not reported |
| Part 2: Non-tBRCA LOH+ | 14.7 | Not reported | 10.8 | 19.8 | Not reported |
| Part 2: Non-tBRCA LOH- | 13.3 | Not reported | 9.1 | 16.0 | Not reported |
| Part 2: Non-tBRCA LOH Unknown | 14.1 | Not reported | 7.4 | 20.1 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 16.7
- upper Limit
- 28.6
- value
- 22.7
- group Id
- OG001
- lower Limit
- 10.8
- upper Limit
- 19.8
- value
- 14.7
- group Id
- OG002
- lower Limit
- 9.1
- upper Limit
- 16.0
- value
- 13.3
- group Id
- OG003
- lower Limit
- 7.4
- upper Limit
- 20.1
- value
- 14.1
- denoms
- counts
- group Id
- OG000
- value
- 84
- group Id
- OG001
- value
- 73
- group Id
- OG002
- value
- 107
- group Id
- OG003
- value
- 23
- units
- Participants
- description
- Overall survival (OS) is defined as the number of days from the date of first dose of study drug to the date of death (due to any cause). Patients without a known date of death will be censored on the date the patient was last known to be alive.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients with a deleterious BRCA mutation detected in their tumor.
- id
- OG000
- title
- Part 2: tBRCA
- description
- Patients without a BRCA mutation in their tumor, but have high LOH.
- id
- OG001
- title
- Part 2: Non-tBRCA LOH+
- description
- Patients without a BRCA mutation in their tumor, but have low LOH.
- id
- OG002
- title
- Part 2: Non-tBRCA LOH-
- description
- Patients without a BRCA mutation in their tumor, and have unknown LOH due to missing results and/or failed test result(s).
- id
- OG003
- title
- Part 2: Non-tBRCA LOH Unknown
- param Type
- MEDIAN
- population Description
- Safety population by HRD subgroups: Consist of all Part 2 patients who received at least one dose of rucaparib.
- reporting Status
- POSTED
- time Frame
- All patients in Part 2 were followed for survival, subsequent therapy, and secondary malignancy every 12 weeks until death, loss to follow-up, withdrawal of consent from study or study closure, whichever happened first, up to 7 years.
- title
- Overall Survival (Part 2 of Study)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice